Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.

Department of Hematology and Oncology "L. and A. Seràgnoli", St. Orsola-Malpighi University Hospital, via Massarenti 9, 40138 Bologna, Italy. .
Haematologica (Impact Factor: 5.94). 06/2008; 93(5):770-4. DOI: 10.3324/haematol.12265
Source: PubMed

ABSTRACT In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myeloid leukemia (CML) is a malignant disorder in which the immune system has been described as important for the graft versus leukemia effect after stem cell transplantation. With imatinib at a dose of 400 mg, the current treatment of chronic phase CML does not eradicate the leukemic stem cells. Most of the patients in molecular response remain with leukemic stem cells responsible for relapse if the treatment is discontinued. Recent studies have suggested that interferon may be useful in order to eradicate the quiescent stem cells. The second-generation inhibitors like dasatinib, nilotinib or bosutinib do not eliminate either the stem cells; this leads to the conclusion that either there is a persistence of leukemic stem cells or there is a general phenomenon with TKI. The mechanisms of resistance include high activities of Bcr-Abl and CrkLPhospho, a weak expression ofOCT-1 and high levels of proteins ABCB1 and ABCG2. However, two scientific groups have recently demonstrated the value of interferon alpha as a molecule that may stimulate the turnover and proliferation of hematopoietic stem cells in vivo. This new approach to understanding the mechanism of action of interferon alpha on hematopoietic stem cells supports the use of combination therapy of TKI plus interferon.
    Oncologie 10/2012; 14(10-11). · 0.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with TKIs. We report on the molecular status and long term outcome of 121 patients who were treated in Italy between 1986 and 2000 with IFNα based therapy and who obtained CCyR. After a median follow up of 16.5 years, 74 (61%) patients were switched to standard imatinib: 48 (65%) lost the CCyR on IFNα, and 36 (75%) are alive and in CCyR; 26 (35%) were switched to imatinib when they were still in CCyR on IFNα, and all 26 are alive and in CCyR. Forty-seven patients (39%) were never switched to imatinib: 24 (51%) continued and 23 (49%) discontinued IFNα, respectively, and 39/47 (83%) are alive and in CCyR. At last follow-up, the BCR-ABL transcripts level was available in 96/101 living patients (95%) The BCR-ABL:ABL ratio was between 0.1 and 0.01% (MR(3.0) ) in 17%, and less than 0.01% (MR(4.0) ) in 81% of patients. No patient was completely molecular negative (MR(4.5) or MR(5.0) ). The OS at 10 and 20 years is 92% and 84%, respectively. This study confirms that CCyR achieved with IFNα and maintained with or without imatinib or any other therapy significantly correlates with long term survival in CML patients who mostly have MR(4.0) . Complete molecular response (MR(4.5) or MR(5.0) ) seems to be unecessary for such a long survival. This study further supports development of studies testing the clinical effect of the combinations of TKIs with IFNα.
    American Journal of Hematology 10/2013; · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initial therapy. We analyzed the outcome of 51 consecutive patients with CML who presented with features of AP at the time of diagnosis, including blasts ≥ 15% (n = 6), basophils ≥ 20% (n = 22), platelets < 100 × 10(9)/L (n = 3), cytogenetic clonal evolution (n = 17), or more than 1 feature (n = 3). Patients received initial therapy with imatinib (n = 30), dasatinib (n = 5), or nilotinib (n = 16). The rate of complete cytogenetic response for patients treated with imatinib was 80%, and with dasatinib or nilotinib was 90%. Major molecular response (MMR) (Breakpoint Cluster Region (BCR)-Abelson (ABL)/ABL ≤ 0.1%, International Scale [IS]) was achieved in 69% of patients including complete molecular response (BCR-ABL/ABL ≤ 0.0032% IS) in 49%. MMR rates for patients treated with imatinib were 63%, and with 2GTKIs, 76%. Overall survival at 36 months was 87% with imatinib and 95% with 2GTKIs. TKIs should be considered standard initial therapy for patients with AP at the time of diagnosis.
    Clinical lymphoma, myeloma & leukemia 12/2013;

Full-text (2 Sources)

Available from
Jun 16, 2014